What Verdica's 799 score means for ALKERMES INC
ALKERMES INC's composite score of 799 out of 850 places the entity in the "strong" performance band (740–799). This score reflects aggregated compliance and operational data sourced from state pharmacy boards, the FDA, and the DEA—the three primary regulators overseeing pharmaceutical manufacturers and distributors in the United States.
A score in this range indicates that ALKERMES INC meets or exceeds baseline regulatory requirements across most measured dimensions, with no major red flags in the indexed data. The company maintains valid licensing, demonstrates consistent adherence to manufacturing and distribution standards, and has not triggered significant enforcement actions that would substantially depress the score. However, the score stops short of the "excellent" band (800–850), suggesting there is room for improvement in at least one compliance area or that minor infractions or operational gaps have been recorded.
For a business owner, healthcare provider, or consumer evaluating this entity, a 799 score signals a provider with a solid compliance foundation. It is materially stronger than an "acceptable" performer (670–739) and represents lower regulatory risk than an "elevated" (580–669) or "high risk" (300–579) entity. The lack of indexed customer reviews means this analysis is based exclusively on regulatory filings and compliance data, not on reported customer experiences.
How the sub-scores break down
Product Approval: 850. This perfect sub-score indicates that all pharmaceutical products associated with ALKERMES INC have received required FDA approvals and maintain current status. Products are either approved as new drugs, authorized generics, or eligible over-the-counter formulations. No products are indexed as withdrawn, suspended, or in regulatory limbo. This dimension is typically binary in nature—either a product is approved or it isn't—which is why a perfect score reflects straightforward compliance with FDA marketing authorization requirements.
Manufacturer Profile: 720. This sub-score reflects the company's operational and organizational compliance standing. At 720, it is notably lower than the product approval score, suggesting minor issues or gaps in manufacturing infrastructure, quality systems, or organizational licensing. Possible factors could include past facility inspections with minor findings, regulatory correspondence requiring corrective action, or licensing lapses that have since been remedied. This score does not indicate systemic failure but rather the kind of operational friction common in large-scale manufacturing.
FDA Compliance: 830. This high sub-score reflects adherence to FDA manufacturing standards (Current Good Manufacturing Practice, or CGMP), quality control protocols, adverse event reporting, and ongoing regulatory correspondence. An 830 score indicates the company has not triggered significant FDA warning letters, import alerts, or consent decrees. Minor inspection observations or routine corrective action requests may be reflected in the score, but the overall compliance trajectory is positive.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records, track facility inspections, and monitor disciplinary actions against entities. The FDA oversees drug approvals, manufacturing practices, facility inspections, and compliance with labeling and adverse event reporting standards. The DEA tracks controlled substance manufacturing quotas, diversion prevention, and license maintenance for entities handling scheduled drugs.
Low scores in these dimensions typically result from repeated inspection failures, failure to implement corrective actions, product recalls, licensing lapses, diversion incidents, or enforcement actions such as warning letters or consent decrees. High scores reflect proactive compliance cultures, timely corrective action, valid licensing, and clean inspection histories. Most entities score between 670 and 799—the range where minor infractions or operational gaps coexist with overall regulatory alignment.
Bottom line
ALKERMES INC presents a strong regulatory profile with an A-grade composite score and no indexed customer concerns. The company is appropriately licensed, maintains FDA product approvals, and demonstrates solid compliance across measured dimensions. Anyone considering a business relationship should cross-check current DEA and state pharmacy licensing status and review any publicly available FDA inspection reports to understand the context behind the lower manufacturer profile sub-score.